The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.

Abstract:

INTRODUCTION:Guidelines provide recommendations on the management of multiple myeloma (MM), but there are no standard algorithms for the choice and sequencing of treatments. As a result, there is widespread variation in the interpretation and implementation of these guidelines. Areas covered: This review will cover: the real-world data on MM treatment patterns; the approved agents available for the treatment of MM; a comparative summary of the national and international clinical guidelines; a discussion on the impact reimbursement decisions have on treatment availability. Expert commentary: In the future, treatment choices may become even more complex as clonal heterogeneity is better understood in the context of response to treatment, and next-generation agents become available. Although information on real-world practice patterns can provide further guidance, to date, few studies have generated data on patients treated with the newer agents in real-world settings. Furthermore, the translation of guideline recommendations into clinical practice across Europe is inconsistent. Additional real-world data are therefore vital to understanding current clinical practice patterns, so that new agents can be effectively incorporated into existing treatment strategies. Such information may aid the development of better guidance, which will ultimately help to ensure that patients receive the best possible care.

journal_name

Expert Rev Hematol

authors

Cavo M,Terpos E,Bargay J,Einsele H,Cavet J,Greil R,de Wit E

doi

10.1080/17474086.2018.1437345

subject

Has Abstract

pub_date

2018-03-01 00:00:00

pages

219-237

issue

3

eissn

1747-4086

issn

1747-4094

journal_volume

11

pub_type

杂志文章,评审
  • Akt signaling in platelets and thrombosis.

    abstract::Akt is a Ser-Thr kinase with pleiotropic effects on cell survival, growth and metabolism. Recent evidence from gene-deletion studies in mice, and analysis of human platelets treated with Akt inhibitors, suggest that Akt regulates platelet activation, with potential consequences for thrombosis. Akt activation is regula...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.09.75

    authors: Woulfe DS

    更新日期:2010-02-01 00:00:00

  • Analysis of Hb levels and degree of anemia in relation to genotype in 615 patients with hemoglobin H disease.

    abstract:OBJECTIVES:We analyzed hemoglobin (Hb) levels and degree of anemia in relation to genotype in patients with hemoglobin H (Hb H) disease, thereby providing a scientific basis for the prevention and treatment of Hb H disease in the Guangxi region of China. METHODS:Hb analysis was conducted in 615 patients using high per...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1803736

    authors: Luo S,Chen X,Chen L,Zhong Q,Wang Q,Xu Z,Huang J,Yan T,Tang N

    更新日期:2020-09-01 00:00:00

  • Mitochondria and Iron: current questions.

    abstract:INTRODUCTION:Mitochondria are cellular organelles that perform numerous bioenergetic, biosynthetic, and regulatory functions and play a central role in iron metabolism. Extracellular iron is taken up by cells and transported to the mitochondria, where it is utilized for synthesis of cofactors essential to the function ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1268047

    authors: Paul BT,Manz DH,Torti FM,Torti SV

    更新日期:2017-01-01 00:00:00

  • Iron overload and allogeneic hematopoietic stem-cell transplantation.

    abstract::Iron overload is frequently observed in patients with hematologic diseases before and after allogeneic stem-cell transplantation because they usually receive multiple red blood cell transfusions. Elevated pretransplant serum ferritin levels, which are widely used as indicators of body iron status, are significantly as...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.10.81

    authors: Kanda J,Kawabata H,Chao NJ

    更新日期:2011-02-01 00:00:00

  • Factor VIII therapy for hemophilia A: current and future issues.

    abstract::Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic u...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.899896

    authors: Aledort L,Ljung R,Mann K,Pipe S

    更新日期:2014-06-01 00:00:00

  • Point mutations which should not be overlooked in Hb H disease.

    abstract:BACKGROUND:Hb H disease is an alpha-thalassemia (α-thal) syndrome characterized by chronic hemolytic anemia that occurs when three of total four α-globin genes lost their function due to completely deletions or different kind of mutations. OBJECTIVE:We here described 66 patients who have been diagnosed for Hb H diseas...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/17474086.2016.1107470

    authors: Farashi S,Bayat N,Vakili S,Faramarzi Garous N,Ashki M,Imanian H,Najmabadi H,Azarkeivan A

    更新日期:2016-01-01 00:00:00

  • The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.

    abstract::Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery. Due to the high incidence of venous thromboembolism in this setting, perioperative anticoagulation is the recommended approach for thromboprophylaxis. Low molecular weight heparin (LMWH), fondapar...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2013.853430

    authors: Rachidi S,Aldin ES,Greenberg C,Sachs B,Streiff M,Zeidan AM

    更新日期:2013-12-01 00:00:00

  • Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.

    abstract::Introduction: Secondary central nervous system lymphoma (SCNSL) is a potentially fatal event in the setting of aggressive Non-Hodgkin Lymphomas. Nowadays, despite of the very poor outcome of SCNSL, several studies are going to identify the high-risk patients' subgroup that could early develop this detrimental event an...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1643232

    authors: Santambrogio E,Nicolosi M,Vassallo F,Castellino A,Novo M,Chiappella A,Vitolo U

    更新日期:2019-09-01 00:00:00

  • Sickle cell disease as a vascular disorder.

    abstract:INTRODUCTION:In sickle cell disease (SCD), hemoglobin S (HbS) red blood cells (RBCs) are characteristically deformed and inflexible. Often breaking down in the circulation, they exhibit increased adhesive properties with the endothelium and activated neutrophils and platelets, increasing the risk of occlusion of the mi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1758555

    authors: Ofori-Acquah SF

    更新日期:2020-06-01 00:00:00

  • Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.

    abstract::Human acute myeloid leukemia is a heterogeneous disease and the effect of therapeutic targeting of specific molecular mechanisms will probably vary between patient subsets. Cell cycle regulators are among the emerging targets (e.g., aurora and polo-like kinases, cyclin-dependent kinases). Inhibition of communication b...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2015.1032935

    authors: Reikvam H,Hauge M,Brenner AK,Hatfield KJ,Bruserud Ø

    更新日期:2015-06-01 00:00:00

  • Update on current research into haploidentical hematopoietic stem cell transplantation.

    abstract:INTRODUCTION:Haploidentical stem cell transplantation (Haplo-SCT) is currently a suitable alternative worldwide for patients with hematological diseases, who lack human leukocyte antigen (HLA)-matched siblings or unrelated donors. Areas covered: This review summarizes the advancements in Haplo-SCT in recent years, prim...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1447379

    authors: Sun YQ,Chang YJ,Huang XJ

    更新日期:2018-04-01 00:00:00

  • An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.

    abstract::Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, consumption thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, the specific von Willebrand factor (VWF)-cl...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1611423

    authors: Joly BS,Coppo P,Veyradier A

    更新日期:2019-06-01 00:00:00

  • Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review.

    abstract:INTRODUCTION:Recent advances and drug approvals in the last decade have substantially changed the landscape of relapsed and refractory multiple myeloma (RRMM), which not only improved outcomes for patients but also increased complexity of treatment decisions. The approvals are based on randomized studies of novel agent...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1804356

    authors: Sanchez L,Barley K,Richter J,Franz J,Cho HJ,Jagannath S,Madduri D,Parekh S,Richard S,Chari A

    更新日期:2020-09-01 00:00:00

  • Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options.

    abstract:INTRODUCTION:Large granular lymphocytic leukemia (LGLL) is a low grade lymphoproliferative disorder characterized by the clonal proliferation of large granular lymphocytes (LGL) and recognised by the WHO. The diagnosis and management of these patients is challenging due to the limited information from prospective studi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1284585

    authors: Matutes E

    更新日期:2017-03-01 00:00:00

  • FLT3 inhibitors in acute myeloid leukemia.

    abstract::The fms-like tyrosine kinase 3 (FLT3) plays an important role in both normal and malignant hematopoiesis. Activating mutations in the FLT3 receptor can be detected in approximately 30% of acute myeloid leukemias (AMLs) and are associated with a distinctly poor clinical outcome for patients. There are now several class...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.1.2.153

    authors: el-Shami K,Stone RM,Smith BD

    更新日期:2008-12-01 00:00:00

  • Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.

    abstract::Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1142370

    authors: Figueiredo L,Cole PD,Drachtman RA

    更新日期:2016-03-01 00:00:00

  • Diagnosis and management of factor V Leiden.

    abstract:INTRODUCTION:The discovery of the factor V Leiden (FVL) missense mutation (Arg506Gln) causing factor V resistance to the anticoagulant action of activated protein C was a landmark that allowed a better understanding of the basis of inherited thrombotic risk. FVL mutation is currently the most common known hereditary de...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1249364

    authors: Campello E,Spiezia L,Simioni P

    更新日期:2016-12-01 00:00:00

  • Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?

    abstract:INTRODUCTION:First and second generation tyrosine kinase inhibitors, represent a new, fully biologic and targeted approach to chronic lymphocytic leukemia and allowed to obtain high responses and acceptable tolerability even in elderly and high risk patients. On the other hand, prolonged experience with these agents ha...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1191943

    authors: Frustaci AM,Montillo M,Picardi P,Mazzucchelli M,Cairoli R,Tedeschi A

    更新日期:2016-07-01 00:00:00

  • Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.

    abstract::Indolent non-Hodgkin's lymphoma (iNHL) describes a group of B-cell lymphomas with a long median survival and a relapsing-remitting clinical course. Although existing treatments are initially effective, patients often relapse, demonstrating decreasing efficacy with successive treatment courses. Alternative treatments a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2015.1071663

    authors: Davies A

    更新日期:2015-10-01 00:00:00

  • How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.

    abstract:INTRODUCTION:Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor that has shown superiority as compared to available conventional chemotherapies, in terms of reduction in splenomegaly and improvement of symptoms and quality of life. Areas covered: Data published about overall survival in the major randomized spon...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1273766

    authors: Massaro F,Molica M,Breccia M

    更新日期:2017-02-01 00:00:00

  • What does the 'Cochrane database of systematic reviews' tell us about hemophilia?

    abstract::Introduction: The purpose of this article is to review which data about hemophilia are currently provided by the Cochrane database of systematic reviews (CDBSR). Methodological consideration: All statements about hemophilia in the Cochrane Collaboration are based on evidence generated in randomized controlled clinical...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2019.1676718

    authors: Rodriguez-Merchan EC

    更新日期:2019-11-01 00:00:00

  • Eltrombopag for the treatment of immune thrombocytopenia.

    abstract::Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count that has persisted for more than 12 months. Patients with severe, symptomatic disease may have significant morbidity and require treatment. Historically, the underlying cause of ITP was believed to be accelerated plat...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.11.25

    authors: Cheng G

    更新日期:2011-06-01 00:00:00

  • Current and future prospects for hemophilia gene therapy.

    abstract::Here we review the recent literature on Hemophilia gene transfer/therapy. Gene therapy is one of several new technologies being developed as a treatment for bleeding disorders. We will discuss current and pending clinical efforts and attempt to relate how the field is trending. In doing so, we will focus on the use of...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1182859

    authors: Ward P,Walsh CE

    更新日期:2016-07-01 00:00:00

  • Prognostic factors for multiple myeloma in the era of novel therapies.

    abstract:INTRODUCTION:Multiple myeloma (MM) is characterized by notable inter-patient and intra-clonal heterogeneity that is gradually decoded over the last decade. Despite the deeper and better understanding of its biology and the development of novel therapeutic strategies that have prolonged overall survival, MM still retain...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/17474086.2018.1537776

    authors: Ziogas DC,Dimopoulos MA,Kastritis E

    更新日期:2018-11-01 00:00:00

  • Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.

    abstract::β-thalassemias are caused by nearly 300 mutations of the β-globin gene, leading to a low or absent production of adult hemoglobin (HbA). Two major therapeutic approaches have recently been proposed: gene therapy and induction of fetal hemoglobin (HbF) with the objective of achieving clinically relevant levels of Hbs. ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.13.24

    authors: Breda L,Rivella S,Zuccato C,Gambari R

    更新日期:2013-06-01 00:00:00

  • Optimizing management of myelodysplastic syndromes post-allogeneic transplantation.

    abstract::Allogeneic hematopoietic stem cell transplantation is still the only potentially curative treatment for patients with myelodysplastic syndromes. Improvements in donor selection, supportive care and the introduction of reduced-intensity conditioning have led to a decrease in early transplant mortality. However, relapse...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.11.58

    authors: Sockel K,Ehninger G,Hofbauer LC,Platzbecker U

    更新日期:2011-12-01 00:00:00

  • Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

    abstract::Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.932687

    authors: Al-Hussaini M,DiPersio JF

    更新日期:2014-08-01 00:00:00

  • Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma.

    abstract:INTRODUCTION:Immune surveillance is the dynamic process whereby the immune system identifies and kills tumor cells based on their aberrant expression of stress-related surface molecules or presentation of tumor neoantigens. It plays a crucial role in controlling the initiation and progression of hematologic cancers suc...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1755958

    authors: Nesic M,El-Galaly TC,Bøgsted M,Pedersen IS,Dybkær K

    更新日期:2020-06-01 00:00:00

  • Immunotherapy for the treatment of Hodgkin lymphoma.

    abstract:INTRODUCTION:Most patients with Hodgkin lymphoma (HL) enjoy durable remissions following front-line treatment but 30% of patients are refractory or relapse after first line therapy. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) can cure an additional 50-55% of relapsing patients but new t...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1313701

    authors: Donato EM,Fernández-Zarzoso M,De La Rubia J

    更新日期:2017-05-01 00:00:00

  • One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic

    abstract::Key paper evaluation: Craddock C, et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2019; 37: 580-8. Allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only potentially cura...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2019.1635005

    authors: Bewersdorf JP,Stahl M,Zeidan AM

    更新日期:2019-08-01 00:00:00